List view / Grid view
Data in the NEURO-TTRansform study demonstrates that eplontersen had a positive impact on disease progression, including improvement in neuropathy impairment and quality of life in a substantial number of patients.
AstraZeneca has entered into a new global development and commercialisation agreement with Ionis Pharmaceuticals for eplontersen.
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
Ionis Pharmaceuticals' Phase III trial to evaluate AKCEA-APOCIII-LRx in patients with familial chylomicronemia syndrome has begun.
1 June 2017 | By Niamh Marriott, Junior Editor
The EC has granted marketing authorisation for Ionis Pharmaceuticals’ Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA)...
23 March 2017 | By Niamh Marriott, Junior Editor
Akcea Therapeutics' pivotal Phase 3 study of volanesorsen reduced triglyceride levels in patients with familial chylomicronaemia syndrome...
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
13 January 2016 | By Victoria White
IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus...
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
18 December 2015 | By Victoria White
Explaining his reasoning behind the company name change, Stanley Crooke, CEO of Ionis, told Forbes: “My underlying concern was that the name was a distraction"...
